HumanaMedicare Advantage · Coverage · Medicare Advantage · Hematology, Genetics, Family Medicine +2 moreMedium impact
Genetic and Coagulation Testing for Noncancer Blood Disorders - Medicare Advantage (Revised)
Effective date
Feb 2, 2026
Identified
Jun 24, 2026
Summary
Humana Medicare Advantage has revised its policy for genetic and coagulation testing for noncancer blood disorders, updating coverage determinations and limitations for conditions like hemophilia, thalassemia, and clotting disorders. The policy consolidates requirements for genetic testing related to blood coagulation issues and references multiple MolDX Local Coverage Determinations across different Medicare Administrative Contractor jurisdictions.
Get alerts when payers change rules like this one
We check Humana and other payers every day and email you when a change matches your specialty and state.
01Before February 2, 2026: Review and update prior authorization processes for genetic and coagulation testing orders for noncancer blood disorders.
02Billing team must verify coverage requirements against applicable MolDX Local Coverage Determinations based on practice location and ensure documentation supports medical necessity for tests related to hemophilia, thalassemia, G6PD deficiency, and other inherited blood disorders.
03Update encounter forms to remind providers of revised coverage limitations.
Original notice
Genetic and Coagulation Testing for Noncancer Blood Disorders - Medicare Advantage (Revised)
mcp.humana.com · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.